Prof Scott Webster, Chief Technology Officer, Kynos Therapeutics Ltd

photo of Prof Scott Webster

Scott is founder and Chief Technology Officer of Kynos Therapeutics and Professor of Medicines Discovery at the University of Edinburgh. Following a period working in biotech he joined the Centre for Cardiovascular Science at the University of Edinburgh where he built a drug discovery team and led its first project from inception through to Phase I studies and out-licensing. With his university colleague, Damian Mole, his team was also part of a fruitful Discovery Partnerships with Academia collaboration (DPAc) with GSK to identify small molecule inhibitors of KMO for the treatment of acute pancreatitis. Following a strategic decision by GSK to close all DPAc programmes he and Damian formed Kynos Therapeutics where they are developing their portfolio of KMO inhibitors for the treatment of a range of acute and chronic inflammatory conditions.

Presentation Title: Manufacturing KNS366 from Spinout to First in Human Studies

Abstract: Kynos Therapeutics is a spinout company arising from a previous collaboration between the University of Edinburgh and GSK. Kynos co-founder, Prof Scott Webster, will outline the issues facing a new company to create the infrastructure required to transfer assets from large pharma and implement manufacture of drug product for intravenous administration in a Phase I clinical trial.

View company profile